Trobix Bio develops precision human microbiome therapeutics using its TBX technology platform, which combines CRISPR, engineered phages, and synthetic biology to deliver targeted DNA cargo to specific gut bacteria. This approach enables the in vivo production of biotherapeutics for metabolic inflammatory and cancer diseases, addressing the challenges of microbiome dysbiosis and transient bacterial colonization.
Funding
$8.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current microbiome therapies often struggle with effective bacterial colonization and demonstrate transient efficacy due to the dynamic nature of the gut microbiome and challenges in addressing dysbiosis. Traditional approaches like fecal microbiota transplantation (FMT) or live bacterial products (LBP) face limitations in achieving robust and durable therapeutic outcomes.
Solution
Trobix Bio develops precision microbiome therapeutics using its TBX technology platform to overcome the limitations of existing approaches. The TBX platform leverages engineered bacteriophages to deliver targeted DNA payloads, combining CRISPR and synthetic biology to modulate the gut microbiome from within. This enables in vivo production of biotherapeutics by harnessing the patient's own microbiome bacteria as a production port, leading to more robust and durable efficacy without disrupting the overall microbiome composition. The platform's oral delivery mechanism simplifies administration and enhances targeted action within the gut.
Target Audience
The primary target audience includes pharmaceutical companies and researchers focused on developing novel therapies for metabolic diseases, inflammatory conditions, and cancer, as well as patients who could benefit from more effective and durable microbiome-based treatments.
Features
- TBX technology platform utilizing engineered bacteriophages for targeted DNA cargo delivery to specific gut bacteria.
- Combines CRISPR and synthetic biology for in vivo biotherapeutic production.
- Oral delivery for ease of administration and targeted action.
- Designed for robust and durable efficacy without disrupting the microbiome.
- Potential applications in metabolic, inflammatory, and cancer diseases.